Please login to the form below

Not currently logged in
Email:
Password:

cinacalcet

This page shows the latest cinacalcet news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... Specifically, it is administered three times a week as an infusion at the end of the dialysis process, while cinacalcet

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on dialysis who develop secondary hyperparathyroidism (sHPT).

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    The rejection is a big disappointment for Amgen, which had suggested that Parsabiv (also known as velcalcetide and AMG 416) could equal and potentially exceed Sensipar (cinacalcet) as a revenue driver.

  • Amgen's Sensipar follow-up clears phase III trial Amgen's Sensipar follow-up clears phase III trial

    Now, Amgen is edging close to bringing a successor to Sensipar (cinacalcet) to market after follow-up AMG 416 (formerly known as velcalcetide) met its objectives in a phase III trial

  • Amgen profits down on rising costs Amgen profits down on rising costs

    Among Amgen's other new products, Sensipar/Mimpara (cinacalcet) for hyperparathyroidism grew 19 per cent to $256m, while Xgeva and Prolia (both denosumab) for preventing bone fractures rose 72 per cent

  • Amgen buoyant as profits rise in Q3 Amgen buoyant as profits rise in Q3

    Hyperparathyroidism drug Sensipar/Mimpara (cinacalcet) had a good quarter, up 18 per cent to $243m, while colorectal cancer drug Vectibix (panitumumab) rose 11 per cent to $88m.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics